Abstract
We have previously reported the structure-based optimisation of a number of series of potent compounds progressed as clinical candidates for oncology through inhibition of the ATPase activity of the molecular chaperone, Hsp90. The starting point for these candidates was compounds discovered using a combination of structure-based hit identification methods. This chapter summarises the overall story of how these methods were applied. Virtual screening of commercially available compounds identified a number of classes of compounds. At the same time, an initial fragment screen identified 17 fragments of various classes that bound to the N-terminal domain of Hsp90 with weak (0.5–10 mM) affinity. A subsequent screen identified a total of 60 compounds. This collection of fragments and virtual screening hits were progressed in a number of ways. Although two fragments could be observed binding together in the active site, the synthetic effort required to link these fragments was judged too high. For the resorcinol class of fragments, limited library synthesis generated compounds in the 1–10 μM range. In addition, the resorcinol substructure was used to select commercially available compounds that were filtered using focussed docking in the Hsp90 active site to select further sets of compounds for assay. This identified structural motifs that were exploited during lead optimisation to generate AUY922, currently in Phase II clinical trials. In a separate campaign, features identified in the structures of fragments, evolved fragments and virtual screening hits bound to Hsp90 were combined to generate an oral series of compounds, progressed to preclinical candidates. The crystal structures were determined of many of the fragments bound to Hsp90 and provide examples of both maintenance and change of protein conformation on fragment binding. Finally, we analyse the extent to which our initial set of fragments recapitulates the key structural features of the Hsp90 inhibitors published to date.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dutta D et al (2009) The molecular chaperone heat shock protein-90 positively regulates rotavirus infectionx. Virology 391(2):325–333
Dollins DE et al (2007) Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 28(1):41–56
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761–772
Trepel J et al (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537–549
Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305–315
Soga S, Shiotsu Y, Akinaga S, Sharma SV (2003) Development of radicicol analogues. Curr Cancer Drug Targets 3(5):359–369
Gao Z, Garcia-Echeverria C, Jensen MR (2010) Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Dev 13(2):193–202
Taldone T et al (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8(4):370–374
Eccles SA et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8):2850–2860
Brough PA et al (2008) 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51(2):196–218
Lundgren K et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 8(4):921–929
Wang Y et al (2010) STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11(12):1466–1476
Huang KH et al (2009) Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52(14):4288–4305
Woodhead AJ et al (2010) Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-di hydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53(16):5956–5969
Biamonte MA et al (2010) Heat shock protein 90: inhibitors in clinical trials. J Med Chem 53(1):3–17
Brough PA et al (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 52(15):4794–4809
Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271–294
Wright L et al (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 11(6):775–785
Chiosis G et al (2003) Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 3(5):371–376
Obermann WM et al (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143(4):901–910
Leach AR, Shoichet BK, Peishoff CE (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49(20):5851–5855
Warren GL et al (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49(20):5912–5931
Barril X, Morley SD (2005) Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem 48(13):4432–4443
Baurin N et al (2004) Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci 44(2):643–651
Irwin JJ, Shoichet BK (2005) ZINC–a free database of commercially available compounds for virtual screening. J Chem Inf Model 45(1):177–182
Stebbins CE et al (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89(2):239–250
Morley SD, Afshar M (2004) Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock. J Comput Aided Mol Des 18(3):189–208
Aherne W et al (2003) Assays for HSP90 and inhibitors. Methods Mol Med 85:149–161
Brough PA et al (2005) 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 15(23):5197–5201
Cheung KM et al (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15(14):3338–3343
Howes R et al (2006) A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 350(2):202–213
Barril X et al (2005) Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 15(23):5187–5191
Murray CW et al (2010) Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 53(16):5942–5955
Panaretou B et al (2002) Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10(6):1307–1318
Baurin N et al (2004) Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 44(6):2157–2166
Hubbard RE et al (2007) The SeeDs approach: integrating fragments into drug discovery. Curr Top Med Chem 7(16):1568–1581
Congreve M et al (2008) Recent developments in fragment-based drug discovery. J Med Chem 51(13):3661–3680
Fischer M, Hubbard RE (2009) Fragment-based ligand discovery. Mol Interv 9(1):22–30
Schulz MN, Hubbard RE (2009) Recent progress in fragment-based lead discovery. Curr Opin Pharmacol 9(5):615–621
Shuker SB et al (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274(5292):1531–1534
Huth JR et al (2007) Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des 70(1):1–12
Oltersdorf T et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677–681
Hajduk PJ (2006) SAR by NMR: putting the pieces together. Mol Interv 6(5):266–272
Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6(3):211–219
Howard N et al (2006) Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J Med Chem 49(4):1346–1355
Barker JJ et al (2010) Discovery of a novel Hsp90 inhibitor by fragment linking. ChemMedChem 5(10):1697–1700
Barker JJ et al (2009) Fragment-based identification of Hsp90 inhibitors. ChemMedChem 4(6):963–966
Dymock BW et al (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48(13):4212–4215
Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5(9):730–739
Chiosis G, Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1(5):279–284
Hubbard RE (2008) Fragment approaches in structure-based drug discovery. J Synchrotron Radiat 15(Pt 3):227–230
Massey AJ et al (2010) Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 9(4):906–919
Fadden P et al (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 17(7):686–694
Hubbard RE, Murray JB (2011) Experiences in fragment-based lead discovery. Methods Enzymol 493:509–531
Dymock B et al (2004) Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett 14(2):325–328
Roughley SD, Hubbard RE (2011) How well can fragments explore accessed chemical space? A case study from Heat Shock Protein 90. J Med Chem. DOI: 10.1021/jm200350g
Acknowledgements
The Hsp90 project was a substantial effort which involved most members of Vernalis at one time or another. Of particular significance was the contributions of Xavier Barril, who provided the inspirational contributions in virtual screening and molecular modelling and of Ben Davis, who remains the principal driver of the development of the NMR techniques and fragment screening strategies at Vernalis. The medicinal chemistry and project leadership in the early stages was provided by Brian Dymock and Martin Drysdale successfully led the collaboration with Novartis through to the various preclinical candidates. The other members of the Hsp90 team are listed in the references [11, 17, 19, 30, 32, 33, 36, 49, 56]. The project was collaboration with the group of Paul Workman at the ICR for the discovery of AUY922 who provided much of the in vivo biology and DMPK testing for that phase of the project. The subsequent preclinical and clinical development of AUY922 and the campaigns that led to BEP800 are a collaboration with Novartis.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin-Heidelberg
About this chapter
Cite this chapter
Roughley, S., Wright, L., Brough, P., Massey, A., Hubbard, R.E. (2011). Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening. In: Davies, T., Hyvönen, M. (eds) Fragment-Based Drug Discovery and X-Ray Crystallography. Topics in Current Chemistry, vol 317. Springer, Berlin, Heidelberg. https://doi.org/10.1007/128_2011_181
Download citation
DOI: https://doi.org/10.1007/128_2011_181
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27539-5
Online ISBN: 978-3-642-27540-1
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)